Key Highlights
- Faeth Therapeutics shares closed up 9% at $28.19.
- Citizens initiated coverage with a Market Outperform rating.
- The firm set a price target of $51.
- Faeth Therapeutics is an oncology-focused biotechnology company.
Faeth Therapeutics (NASDAQ: FTH) shares closed up 9% at $28.19 after the company received a new Market Outperform rating from a Citizens analyst, who initiated coverage with a price target of $51.
What Happened
Citizens initiated coverage on the oncology-focused biotechnology company with a Market Outperform rating, implying substantial upside from the stock's closing price of $28.19.
The disclosed information does not include additional detail on the specific rationale behind the rating or price target.
Market Reaction
Shares rose 9% to close at $28.19 following the new coverage initiation, reflecting a positive investor response to the bullish analyst rating.
The $51 price target represents significant implied upside from the stock's current trading level, according to the disclosed information.
Outlook
The disclosed information does not include additional forward guidance beyond the new Citizens rating and price target.
Why did Faeth Therapeutics shares rise 9%?
Shares rose after Citizens initiated coverage on the stock with a Market Outperform rating.
What is Citizens' price target on Faeth Therapeutics?
Citizens set a price target of $51.
What kind of company is Faeth Therapeutics?
It is an oncology-focused biotechnology company.






Please wait processing your request...